1,331 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 1,331 shares of the company’s stock, valued at approximately $101,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its holdings in AstraZeneca by 17.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after acquiring an additional 9,002,450 shares during the period. Capital World Investors grew its holdings in AstraZeneca by 0.3% during the first quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after acquiring an additional 29,497 shares during the period. Envestnet Asset Management Inc. grew its holdings in AstraZeneca by 16.7% during the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after acquiring an additional 488,644 shares during the period. Clearbridge Investments LLC grew its holdings in AstraZeneca by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after acquiring an additional 186,010 shares during the period. Finally, Fayez Sarofim & Co grew its holdings in AstraZeneca by 4.7% during the first quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock worth $202,588,000 after acquiring an additional 134,784 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 3.2 %

AZN opened at $72.83 on Thursday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The firm has a market cap of $225.82 billion, a P/E ratio of 35.18, a PEG ratio of 1.39 and a beta of 0.46. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The business’s fifty day simple moving average is $79.77 and its 200 day simple moving average is $78.64.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Finally, TD Cowen raised their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.